-
2 months ago | 
mdpi.com | Hope Rugo |Aditya Bardia |Peter Schmid |Sara M. Tolaney
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jan 22, 2025 | 
targetedonc.com | Rohit Gosain |Rahul Gosain |Sara M. Tolaney
Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its potential to expand treatment options for this subgroup.
-
Jan 22, 2025 | 
targetedonc.com | Rohit Gosain |Rahul Gosain |Sara M. Tolaney
Panelists discuss the results and implications of the DESTINY-Breast06 study, highlighting the efficacy of trastuzumab deruxtecan in patients with HER2-positive breast cancer previously treated with multiple lines of therapy.
-
Jan 22, 2025 | 
targetedonc.com | Rohit Gosain |Rahul Gosain |Sara M. Tolaney
Panelists discuss the PATINA study, examining the role of palbociclib in combination with letrozole as a first-line treatment for hormone receptor–positive, HER2-negative breast cancer, and its impact on progression-free survival.
-
Oct 30, 2024 | 
healio.com | Sara M. Tolaney |Savannah Demko |Mindy Valcarcel
October 30, 2024 2 min watch VIDEO: T-DXd shows promise for patients with HER2-positive with brain metastases Add topic to email alerts Please provide your email address to receive an email when new articles are posted on Breast Cancer. Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Oct 30, 2024 | 
healio.com | Sara M. Tolaney |Savannah Demko |Mindy Valcarcel
VIDEO: Longer follow-up may increase benefits of ribociclib in some patients with breast cancerSara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial. The data, presented at ESMO Congress, showed the benefit seen after patients with hormone receptor-positive, HER2-negative breast cancer were off ribociclib (Kisqali, Novartis), Tolaney told Healio in a video interview.
-
Oct 30, 2024 | 
healio.com | Sara M. Tolaney |Savannah Demko |Mindy Valcarcel
VIDEO: Pembrolizumab ‘should be standard of care’ for stage II or III triple-negative breast cancerSara M.
-
Oct 30, 2024 | 
nature.com | Johanna Klughammer |Daniel L. Abravanel |Timothy R. Blosser |Yury Goltsev |Chiara Caraccio |Nicole Cullen | +7 more
AbstractAlthough metastatic disease is the leading cause of cancer-related deaths, its tumor microenvironment remains poorly characterized due to technical and biospecimen limitations. In this study, we assembled a multi-modal spatial and cellular map of 67 tumor biopsies from 60 patients with metastatic breast cancer across diverse clinicopathological features and nine anatomic sites with detailed clinical annotations.
-
Oct 9, 2024 | 
nature.com | Naiara Perurena |Yoona Yang |Carrie Rodriguez |Alycia Gardner |Patrick Loi |Yilin Xu | +9 more
AbstractTriple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN3,4,5,6.
-
Oct 8, 2024 | 
erc.bioscientifica.com | Marta Villanova |Sara M. Tolaney |Lê Min
Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
